Discontinued — last reported Q4 '25

Non-Current Liabilities

Finance Lease Liabilities (Total)

Regeneron Pharmaceuticals Finance Lease Liabilities (Total) remained flat by 0.0% to $720.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $720.00M to $720.00M. Over 5 years (FY 2020 to FY 2025), Finance Lease Liabilities (Total) shows relatively stable performance with a 0.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ1 2019
Last reportedQ4 2025

How to read this metric

An increase indicates a preference for financing asset acquisitions through leasing rather than cash or traditional loans, impacting long-term interest expense.

Detailed definition

The aggregate amount of all current and non-current obligations related to finance leases, representing the total debt-e...

Peer comparison

Investors use this to adjust debt metrics to ensure comparability between firms that buy assets and those that use finance leases.

Metric ID: finance_lease_liabilities_total

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$719.70M$720.00M$720.00M$720.00M$720.00M
QoQ Change—+0.0%+0.0%+0.0%+0.0%
YoY Change—+0.0%+0.0%+0.0%+0.0%
Range$719.70M – $720.00M
CAGR+0.0%
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Regeneron Pharmaceuticals's finance lease liabilities (total)?
Regeneron Pharmaceuticals (REGN) reported finance lease liabilities (total) of $720.00M in Q4 2025.
How has Regeneron Pharmaceuticals's finance lease liabilities (total) changed year-over-year?
Regeneron Pharmaceuticals's finance lease liabilities (total) decreased by 0.0% year-over-year, from $720.00M to $720.00M.
What is the long-term trend for Regeneron Pharmaceuticals's finance lease liabilities (total)?
Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's finance lease liabilities (total) has grown at a 0.1% compound annual growth rate (CAGR), from $717.20M to $720.00M.
What does finance lease liabilities (total) mean?
The total debt the company owes for all its lease-to-own agreements.